| Similar Articles |
|---|
 |
Pharmaceutical Executive
June 1, 2005
Joanna Breitstein |
Turn the Page Changes in ethics and expectations are driving the way pharma interacts with medical publishers.   |
Reason
October 2007
Ronald Bailey |
Is Industry-Funded Science Killing You? The overrated risks and underrated benefits of pharmaceutical research "conflicts of interest." |
Pharmaceutical Executive
July 1, 2014
Jill Wechsler |
Pre-emption and States' Rights Pharma backs federal standards for compassionate use, drug importing, data transparency, and track-and-trace. |
The Motley Fool
December 4, 2007
Brian Orelli |
An Early Gift to Drugmakers Drugmakers could be allowed to market for drugs' off-label indications. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
Managed Care
February 2002
Ira Studin |
Reframing the Pharmaceutical Manufacturer/Health Plan Relationship in Managed Care It is suggested that health plans address "total cost-of-care savings" in their budget process, and the pharmaceutical manufacturers establish a "consultative service function" in their managed care divisions... |
Pharmaceutical Executive
July 1, 2013
Ben Comer |
What is a Journal Reprint Worth? Pharma and physicians worry about getting sunburned by the Sunshine Act. |
Pharmaceutical Executive
June 1, 2005
Zimmerman & Fay |
Marketing to Professionals: Dr. Ambassador The pharma industry is under siege in the news media. Smart companies must create a role for physicians as ambassadors who can raise patient confidence in drugs and the pharma industry as a whole. |
Pharmaceutical Executive
September 1, 2006
Patrick Clinton |
From the Editor: Undecided People are buying drugs, because companies are selling drugs. Interfere with the selling process, and people won't buy as many drugs. |
The Motley Fool
September 9, 2009
Brian Orelli |
Don't Like High Drug Costs? Blame Canada. Through a combination of price controls instituted by the Patented Medicine Prices Review Board, and through government negotiations, Canada is able to keep its drug costs down for its citizens. But that doesn't make it right. |
Pharmaceutical Executive
March 1, 2011
Jerry Coamey |
Engage the Physician! New research shows that gauging the mind of the clinician is crucial to timely uptake of the new diagnostic tools offered by the genomic revolution |
Pharmaceutical Executive
August 1, 2006
Patrick Clinton |
From the Editor: Take Your Seat There's a lot to accomplish in the pharmaceutical industry. But considering what the industry has done in 25 years, it's not impossible. |
Pharmaceutical Executive
June 1, 2007
Dinh Nguyen |
Clinical Trials Under Scrutiny Over the last few years, there has been a growing number of instances of misconduct in clinical research. |
BusinessWeek
June 28, 2004
Amy Barrett |
When Medicine And Money Don't Mix Do drugmakers have too much control over lab data? |
Managed Care
April 2000
Tim Olsen |
Physician, Tarnish Not Thine Image Doctors who use the news media to criticize others, rather than initiate a constructive dialog about difficult issues such as antibiotic resistance, help erode the profession's influence. |
Pharmaceutical Executive
February 1, 2009
Patrick Clinton |
Working Together No one who cares about global health can be happy with a system that only "eventually" delivers drugs and vaccines for the planet's neediest people. |
BusinessWeek
October 23, 2006
Arlene Weintraub |
Cracking Down on Pharma Swag Several medical centers are barring their doctors from accepting freebies like pens and lunches from any vendor. Here's why. |
Pharmaceutical Executive
January 1, 2006
Kenneth I. Kaitin |
Opinion: Memo to von Eschenbach FDA's acting commissioner has an opportunity to clarify a lot of misconceptions about the agency's role in regulating drug safety. His first order of business should be to explain exactly what FDA doesn't do. |
Chemistry World
March 7, 2012
Mico Tatalovic |
Croatia to slim down funding for science journals Science journals in Croatia face an uncertain future, with their main funder, the science ministry, announcing changes that will see only the best journals funded. |
Pharmaceutical Executive
October 1, 2011
Jill Wechsler |
At the Helm of Industry As the lead FDA official overseeing the testing and approval of new drugs and biotech therapies for some 20 years, Dr. Janet Woodcock has built a robust and modern drug regulatory system. |
InternetNews
July 27, 2010 |
Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain. |
Pharmaceutical Executive
July 1, 2005
Jill Wechsler |
Washington Report: The e-Bandwagon The federal government is driving e-Rx adoption by establishing standards that Medicare drug plans will have to adopt by 2009, and HHS officials are pushing to make this happen much earlier. |
The Motley Fool
September 25, 2008
Brian Lawler |
Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors. |
Information Today
July 22, 2010 |
New Informahealthcare.com Combines Journals and Books The new service delivers approximately 170 journals and 600 online books. |
Chemistry World
October 8, 2010
Sarah Houlton |
U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
Pharmaceutical Executive
April 1, 2007
Porth & Sillup |
Media Audit: Stop the Presses! The media are becoming more negative and one-sided when it comes to reporting pharmaceutical industry news. |
Bio-IT World
February 2006
Mark D. Uehling |
Pharma's Mixed Response to Trials Database A late December New England Journal of Medicine article detailed Big Pharma's response to mandatory registration of clinical trials. Here are some highlights. |
Reason
May 2007
Jacob Sullum |
Exporting Drug Prices Pharmaceutical companies argue that the higher prices paid by Americans underwrite the research and development that makes new drugs possible, in effect subsidizing consumers in other countries. Reimportation could force our northern neighbors to share that burden. |
The Motley Fool
February 22, 2005
Charly Travers |
Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list. |
Managed Care
July 2001
Harry L. Leider |
HMOs Need To Share Gains of DM Programs Physicians are more likely to buy in if they see better outcomes -- and financial rewards that go with them... |
Pharmaceutical Executive
June 1, 2005
Boschwitz et al. |
Track Patients, Not Prescriptions Why pharma companies reject anonymous patient-level data, and why they can't do without it for long. |
Pharmaceutical Executive
April 1, 2011 |
How US Health Reform Is Hitting Canada Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry. |
Pharmaceutical Executive
October 1, 2006
Patrick Clinton |
From the Editor: In Conflict Structured conflicts keep the pharmaceutical industry functioning, and threatens it when they get out of balance. |
Pharmaceutical Executive
January 1, 2014
Jill Wechsler |
Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing |
Pharmaceutical Executive
June 1, 2012
Jill Wechsler |
Innovation and Collaboration A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market. |
Information Today
December 12, 2011
Robin Peek |
QScience Connect Redefines Scholarly Journals QScience Connect breaks the boundaries of a peer-reviewed traditional scholarly journal that is defined by a discipline or field. |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
BusinessWeek
May 3, 2004
John Carey |
Is Reimporting Drugs A Cheap Fix? Not Really Why reimporting drugs from Canada won't work in the long run |
The Motley Fool
January 12, 2010
Dayana Yochim |
6 Ways to Score Cheap(er) Drugs Stop overpaying for the pills you have to pop with these simple ways to trim your prescription-drug tab. |
Searcher
January 2002
Myer Kutz |
The Scholars Rebellion Against Scholarly Publishing Practices: Varmus, Vitek, and Venting In the decades-long arguments over STM (scientific/technical/medical) journal publishing, mainly about subscription price increases and intellectual property and accessibility issues, one thing has changed in the last few years. Scholars have become involved... |
Pharmaceutical Executive
January 1, 2007
Jill Wechsler |
Washington Report: A Full Plate It's going to be a busy year in Washington for the pharmaceutical industry. Drug safety, unapproved uses, e-data requirements, and a shift to personalized medicine are just a few of the hot issues on tap for 2007. |
Food Engineering
August 1, 2005 |
Feeling Squeezed? According to a new technology company, significant revenue growth can be captured by those in the supply chain who are able to add value to their physical products -- with better information and service -- without overburdening employees and operations. |
Chemistry World
April 2012 |
Opening the Doors of Knowledge Should all journal articles be free to access online? |
Information Today
June 9, 2008 |
Microsoft's Article Authoring Add-In Now Available in Beta A key value of the Article Authoring Add-in is in enabling editors at scientific and technical journals to create article templates, tailored for their individual journals' requirements. |
Pharmaceutical Executive
October 1, 2010 |
When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve? |
Pharmaceutical Executive
May 1, 2005
Ame Wadler |
PR: In the Loop Pharma marketers can help doctors stay abreast of the news. |
Pharmaceutical Executive
June 1, 2006
Jill Wechsler |
Washington Report: Promises to Keep Congress wants pharma to meet study commitments and disclose research results, but no one is giving FDA more resources to enforce its rules. |
Pharmaceutical Executive
January 1, 2007
Sander Flaum |
Leadership: If Bill Gates Ran PhRMA Pharma has a classic image problem. Sometimes the products don't do what they're supposed to. Innovation is key, but too slow. Business practices can look sleazy. What if our spokesman was a guy who'd beaten those problems? |
Pharmaceutical Executive
March 3, 2014
Sillup & Porth |
Pharm Exec: Annual Press Audit 2014 Pharm Exec's latest survey of press issues shows that media coverage continues to remain on balance negative toward the industry, by a slight margin: 47% this year compared to a 46% average over the last seven years. |
